Hiligsmann M - Search Results

1

Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment.

Hiligsmann M, Dellaert BG, Dirksen CD, Watson V, Bours S, Goemaere S, Reginster JY, Roux C, McGowan B, Silke C, Whelan B, Diez-Perez A, Torres E, Papadakis G, Rizzoli R, Cooper C, Pearson G, Boonen A. Hiligsmann M, et al. Rheumatology (Oxford). 2017 Jul 1;56(7):1167-1176. doi: 10.1093/rheumatology/kex071. Rheumatology (Oxford). 2017. PMID: 28398547 Free PMC article.

2

Utility values associated with osteoporotic fracture: a systematic review of the literature.

Hiligsmann M, Ethgen O, Richy F, Reginster JY. Hiligsmann M, et al. Calcif Tissue Int. 2008 Apr;82(4):288-92. doi: 10.1007/s00223-008-9117-6. Epub 2008 Apr 11. Calcif Tissue Int. 2008. PMID: 18404243 Review.

3

[Long-term risk of osteoporotic fracture in Belgium].

Hiligsmann M, Bruyère O, Reginster JY. Hiligsmann M, et al. Rev Med Liege. 2008 Jul-Aug;63(7-8):480-7. Rev Med Liege. 2008. PMID: 18771226 Free article. French.

4

Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women.

Hiligsmann M, Bruyère O, Ethgen O, Gathon HJ, Reginster JY. Hiligsmann M, et al. Bone. 2008 Dec;43(6):991-4. doi: 10.1016/j.bone.2008.08.119. Epub 2008 Sep 10. Bone. 2008. PMID: 18817901

5

[Economic evaluation of osteoporosis screening strategy conducted in the Province of Liège with the cooperation of Liège Province Santé].

Hiligsmann M, Bruyère O, Pire G, Reginster JY. Hiligsmann M, et al. Rev Med Liege. 2008 Oct;63(10):588-94. Rev Med Liege. 2008. PMID: 19009966 Free article. French.

6

Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.

Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Neuprez A, et al. Among authors: hiligsmann m. Adv Ther. 2008 Dec;25(12):1235-56. doi: 10.1007/s12325-008-0125-8. Adv Ther. 2008. PMID: 19066755 Review.

7

Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis.

Hiligsmann M, Ethgen O, Bruyère O, Richy F, Gathon HJ, Reginster JY. Hiligsmann M, et al. Value Health. 2009 Jul-Aug;12(5):687-96. doi: 10.1111/j.1524-4733.2008.00497.x. Value Health. 2009. PMID: 19508659 Free article.

8

Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.

Hiligsmann M, Bruyère O, Reginster JY. Hiligsmann M, et al. Bone. 2010 Feb;46(2):440-6. doi: 10.1016/j.bone.2009.08.052. Epub 2009 Aug 28. Bone. 2010. PMID: 19716940

9

Strontium ranelate: new data on fracture prevention and mechanisms of action.

Reginster JY, Deroisy R, Neuprez A, Hiligsmann M, Zegels B, Bruyere O. Reginster JY, et al. Among authors: hiligsmann m. Curr Osteoporos Rep. 2009 Sep;7(3):96-102. doi: 10.1007/s11914-009-0016-1. Curr Osteoporos Rep. 2009. PMID: 19723468 Review.

10

Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women.

Bruyere O, Varela AR, Adami S, Detilleux J, Rabenda V, Hiligsmann M, Reginster JY. Bruyere O, et al. Among authors: hiligsmann m. Eur J Epidemiol. 2009;24(11):707-12. doi: 10.1007/s10654-009-9381-4. Epub 2009 Aug 29. Eur J Epidemiol. 2009. PMID: 19728118 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page